Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:53:09.727Z.
Calculation as of: 2026-10-06T17:53:09.727Z.
Quote observation: 2026-10-06T17:48:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 717d9e1ca299c0a9e32b76938e5c8cfcb507e231e4f72cb05b36dcb8f57dd66d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Scienture Holdings, Inc.
Market Cap
$5.69M
EV/EBITDA Ratio
N/A
Market Cap
$5.75M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Scienture Holdings, Inc. (SCNX) | $5.69M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.67M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.75M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.81M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.85M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.99M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.32M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
